Corvus Pharmaceuticals Presents Soquelitinib Atopic Dermatitis Trial Data

Bitget2026/11/05 23:57

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Corvus Pharmaceuticals expects soquelitinib SIERRA1 Phase 2 atopic dermatitis topline data in the third quarter of 2027.
PTCL Phase 3 interim futility analysis is due in the first quarter of 2027, with topline data expected at year-end.
Phase 1 atopic dermatitis results showed 75% achieved EASI75; no serious adverse events occurred.
Initial hidradenitis suppurativa Phase 1b data are expected in the first half of 2027.
Cash runway extends into the second quarter of 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Corvus Pharmaceuticals Presents Soquelitinib Atopic Dermatitis Trial Data

You may also like

Crypto prices